# Medipharm Labs Reports 43% Growth in International Medical Cannabis Revenue for 2025 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pharmaceutical-grade-cannabis-revenue-growth-2025/ > **Published:** 2026-03-30T16:03:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:34:51-04:00 > **Clinical Summary:** Medipharm Labs reports 43% pharmaceutical-grade cannabis revenue growth in 2025, reflecting expanding international medical cannabis markets. --- ✦ New CED Clinical Relevance  #84High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic Market AccessProduct QualityInternational PolicyPharmaceutical Standards Why This Matters International revenue growth for pharmaceutical-grade cannabis companies reflects expanding global acceptance of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) as legitimate therapy. This market expansion may improve [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to standardized, quality-controlled cannabis products across different healthcare systems. Clinical Summary Medipharm Labs reported 43% growth in international [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) revenue for 2025, indicating continued expansion of medical cannabis markets beyond traditional North American jurisdictions. The company focuses on pharmaceutical-grade cannabis concentrate production and international distribution. This growth pattern suggests increasing integration of medical cannabis into established healthcare frameworks internationally, though specific clinical outcomes or [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) improvements are not detailed in the financial reporting. Dr. Caplan’s Take “Financial growth in pharmaceutical-grade cannabis reflects what I see clinically — growing institutional acceptance of [cannabis as medicine](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) rather than just policy experiment. The key is whether this translates to better patient access to consistent, quality products.” Clinical Perspective 🧠 Clinicians should monitor whether expanding international cannabis markets improve product standardization and availability for their patients. The growth of pharmaceutical-grade producers may lead to more consistent dosing options and better regulatory oversight, but individual product quality and clinical appropriateness remain physician responsibilities. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Medipharm%20Labs%20sees%2043%25%20growth%20in%20international%20medical%20cannabis%20revenue%20in%202025%20%40drcaplan&url=https%3A//stratcann.com/financials/medipharm-labs-sees-43-growth-in-international-medical-cannabis-revenue-in-2025/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//stratcann.com/financials/medipharm-labs-sees-43-growth-in-international-medical-cannabis-revenue-in-2025/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Medipharm%20Labs%20sees%2043%25%20growth%20in%20international%20medical%20cannabis%20revenue%20in%202025%20--%20via%20%40drcaplan.bsky.social%20https%3A//stratcann.com/financials/medipharm-labs-sees-43-growth-in-international-medical-cannabis-revenue-in-2025/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://stratcann.com/financials/medipharm-labs-sees-43-growth-in-international-medical-cannabis-revenue-in-2025/](https://stratcann.com/financials/medipharm-labs-sees-43-growth-in-international-medical-cannabis-revenue-in-2025/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What are the main topics covered in this cannabis policy update?](#What_are_the_main_topics_covered_in_this_cannabis_policy_update) - [How does this relate to international cannabis policy?](#How_does_this_relate_to_international_cannabis_policy) - [What does “Pharmaceutical Standards” mean for cannabis products?](#What_does_8220Pharmaceutical_Standards8221_mean_for_cannabis_products) - [How might this impact patient access to medical cannabis?](#How_might_this_impact_patient_access_to_medical_cannabis) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned a Clinical Relevance rating of #84, which indicates “High Clinical Relevance.” This means it contains strong evidence or policy relevance with direct clinical implications for healthcare providers and patients. #### What are the main topics covered in this cannabis policy update? The article focuses on four key areas: Market Access, Product Quality, International Policy, and Pharmaceutical Standards. These topics relate to regulatory frameworks and standards that impact medical cannabis availability and quality control. #### How does this relate to international cannabis policy? This update addresses international policy developments that may affect how cannabis products are regulated across different countries. The international scope suggests potential harmonization or coordination of cannabis standards globally. #### What does “Pharmaceutical Standards” mean for cannabis products? Pharmaceutical standards refer to quality control measures, manufacturing practices, and safety protocols that cannabis products must meet. This ensures [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/) have consistent potency, purity, and safety similar to traditional pharmaceuticals. #### How might this impact patient access to medical cannabis? Changes in market access policies and international standards could improve patient access to high-quality [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/). However, stricter pharmaceutical standards might also create regulatory hurdles that could affect availability or pricing. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Medipharm Labs sees 43% growth in international medical cannabis revenue in 2025”, “url”: “https://stratcann.com/financials/medipharm-labs-sees-43-growth-in-international-medical-cannabis-revenue-in-2025/”, “datePublished”: “2026-03-30T18:55:00Z”, “about”: “medipharm labs sees 43 growth international”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Hot Picks: Cannabis consolidation and global demand fuel sector outlook](https://cedclinic.com/cannabis-sector-outlook-2026-market-trends-quality/) Explore how [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) consolidation and rising global demand are shaping the future of medical cannabis markets. [Read More](https://cedclinic.com/cannabis-sector-outlook-2026-market-trends-quality/) [Medicinal Cannabis Export Licenses Take 6.4 Working Days In 2026 – Scoop](https://cedclinic.com/medicinal-cannabis-export-licenses-2026/) Learn about the streamlined export licensing process for medicinal cannabis and its impact on international market growth. [Learn More](https://cedclinic.com/medicinal-cannabis-export-licenses-2026/) [Rubicon Organics Inc. and 4C Labs Launch 1964 Supply Co. Medical Cannabis Products in the U.K](https://cedclinic.com/medical-cannabis-products-uk-1964-supply-co-launch/) Discover new pharmaceutical-grade medical cannabis products entering the UK market from leading producers. [Explore Now](https://cedclinic.com/medical-cannabis-products-uk-1964-supply-co-launch/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).